Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

Researcher comment: Adjuvant mFOLFIRINOX shows benefits over gemcitabine in pancreatic cancer

Presenting author Thierry Conroy provides an overview of the PRODIGE 24 trial showing adjuvant modified FOLFIRINOX outplays gemcitabine in patients with operable pancreatic cancer (3:58).

Read the related news story and watch the accompanying expert commentary.

More on this topic

06-06-2018 | Gastrointestinal cancers | ASCO 2018 | Video

Expert commentary: GI highlights including the PRODIGE 7, PRODIGE 24, and PREOPANC trials

Image Credits